January 31, 2023 10:47 AM EST
R&D
Pharma

No­var­tis' Xo­lair suc­ces­sor hit by an­oth­er PhI­II axe, but food al­ler­gy study con­tin­ues

Kyle LaHucik

Senior Reporter

Once thought to be a near shoe-in suc­ces­sor to Xo­lair, No­var­tis’ bi­o­log­ic lige­lizum­ab hit an­oth­er road­block, with an ad­di­tion­al Phase III scrapped, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times